Mogamulizumab, a monoclonal antibody targeting C-C chemokines receptor 4 via antibody-dependent cellular cytotoxicity, has gained a rapidly growing importance in the management of cutaneous T-cell lymphomas (CTCL). This evidence concerns the gene CCR4 and primary cutaneous T-cell non-Hodgkin lymphoma.